NCT06587061 is a Phase 2 clinical trial of HRS-4642+AG in Pancreatic Cancer, sponsored by Ruijin Hospital.

Who is sponsoring NCT06587061?

NCT06587061 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT06587061?

Interventions in NCT06587061: HRS-4642+AG.

What condition does NCT06587061 study?

NCT06587061 studies Pancreatic Cancer.

Is NCT06587061 still recruiting?

NCT06587061 is currently recruiting now. Last updated 22 May 2026.

Last reviewed 2026-05-22 · How we verify

NCT06587061

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Recruiting now Phase 2 Last updated 22 May 2026

What this trial tests

Phase 2 trial testing HRS-4642+AG in Pancreatic Cancer in 30 participants. Currently enrolling.

Timeline

3 December 2024

Primary endpoint
1 June 2027

1 December 2027

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	3 December 2024
Primary completion	1 June 2027
Estimated completion	1 December 2027
Sites	1 location across China

Drugs / interventions tested

HRS-4642+AG

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 80, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Adverse events (AEs)
Time frame: From the first drug administration to within 30 days for the last dose
AEs are assessed by NCI-CTCAE v5.0
Objective Response Rate (ORR)
Time frame: Up to approximately 6 months
Evaluated by RECIST v1.1

Sponsor's own description

To evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
Peng C, Oberstein PE. · · 2025 · cited 1× · PMID 40884689 · DOI 10.1007/s11864-025-01352-2

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06587061 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 22 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06587061.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing